Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
RPTR MOLNAR
EDTR ZAMORA
FLU SEASON: U.S. PUBLIC HEALTH
PREPAREDNESS AND RESPONSE
WEDNESDAY, DECEMBER 4, 2019
House of Representatives,
Subcommittee on Oversight
and Investigations,
Committee on Energy and Commerce,
Washington, D.C.
The subcommittee met, pursuant to call, at 10:30 a.m., in Room 2123, Rayburn
House Office Building, Hon. Diana DeGette [chairman of the subcommittee] presiding.
Present: Representatives DeGette, Kennedy, Ruiz, Kuster, Castor, Tonko, Clarke,
Peters, Pallone (ex officio), Guthrie, Burgess, McKinley, Griffith, Brooks, Mullin, Duncan,
and Walden (ex officio).
Staff Present: Kevin Barstow, Chief Oversight Counsel; Jesseca Boyer,
Professional Staff Member; Jeff Carroll, Staff Director; Austin Flack, Staff Assistant;
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Waverly Gordon, Deputy Chief Counsel; Tiffany Guarascio, Deputy Staff Director; Zach
Kahan, Outreach and Member Service Coordinator; Chris Knauer, Oversight Staff Director;
Meghan Mullon, Staff Assistant; Tim Robinson, Chief Counsel; Nikki Roy, Policy
Coordinator; Emily Ryan, GAO Detailee; Andrew Souvall, Director of Communications,
Outreach and Member Services; Benjamin Tabor, Policy Analyst; C.J. Young, Press
Secretary; Jennifer Barblan, Minority Chief Counsel, Oversight and Investigations; Brittany
Havens, Minority Professional Staff, Oversight and Investigations; Brannon Rains,
Minority Legislative Clerk; Alan Slobodin, Minority Chief Investigative Counsel, Oversight
and Investigations; and Natalie Sohn, Minority Counsel, Oversight and Investigations.
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Ms. DeGette. The Subcommittee on Oversight and Investigations hearing will
now come to order.
Today, the committee is holding a hearing entitled "Flu Season: U.S. Public
Health Preparedness and Response." The purpose of today's hearing is to examine the
Federal Government's efforts and forecast for the 2019-2020 influenza season and
ongoing influenza-related research and innovation.
The chair now recognizes herself for purposes of an opening statement.
As I said, we're here this morning to discuss the topic of our Nation's preparedness
for this year's flu season. Ensuring our public health agencies have the tools they need
to prepare and respond to seasonal and pandemic flu has and will remain a bipartisan
effort. That's why this is the 11th hearing the committee has held related to influenza
over the last 15 years. And I'm very pleased that we are having this hearing so early at
the beginning of the flu season this year so we can talk about what we predict during this
flu season and also encourage Americans to please, please, please go get their
vaccinations.
According to the CDC, a majority of States are already seeing increased flu activity,
and history has shown that we're still likely weeks away from the first peak of the season
that often occurs December through February.
Today, we have the Nation's leading health experts about how people can better
protect themselves and their children from this illness before peak flu season. And I
want to thank all of our witnesses for being willing to come here year after year to
address this important topic. I really feel like we're getting the band back together
again in a way that I hope will be effective to let Americans know what's happening.
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
You know, we know from past flu seasons that our Nation's preparation and
response efforts are critical. During the particularly severe 2017 and 2018 flu season,
for example, as many as 80,000 people died as a result of the flu. So many people
became sick that hospitals were forced to put tents in parking lots to treat people who
had become ill.
The more recent 2018-2019 flu season was the longest one in a decade. And
again, while it's still too early to tell how severe this year's flu season will be, given the
unpredictability and serious nature we face, the fact that our Nation's flu vaccination
rates continue to be well below our national target of 70 to 90 percent is alarming.
Last year, for example, only 63 percent of children and only 45 percent of adults
received a flu vaccine. While those rates are disappointing, the fact that they are 5 to 8
points higher, respectively, compared to the year before means at least we're going in the
right direction. But we have a lot more to do to protect the public health. I hope that
the witnesses today can provide us an update on the efforts underway to further
strengthen vaccine confidence and improve the annual vaccination rates.
I also look forward to hearing from the witnesses about the effectiveness of the
flu vaccine and what research is underway to improve its efficacy. While last year's
vaccine was up to 44 percent effective against the H1N1 flu strain, which was the initial
flu strain that was circulating, it was only 9 percent effective for the H3N2 strain, which
became the dominant strain at the end of the season.
And I know our witnesses will remind us, even a vaccine with low effectiveness is
still able to protect millions of people from getting sick and help reduce the severity of
symptoms for those who do. And that's why the flu vaccine remains the best tool we
have to protect the public's health during these threatening times. But as I've said
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
numerous times before, we can and will do better to improve the effectiveness.
The NIH recently began conducting the first in-human trials for a universal flu
vaccine -- and I'm really looking forward to hearing about that -- and the National
Influenza Vaccine Task Force was recently established. These developments are
promising, but the importance of a strong public health infrastructure necessary to
prepare for and respond to seasonal flu cannot be overstated.
I have confidence that our Federal, State, and local public health officials have put
us in a strong position to respond to this year's flu season, but there's always more work
to be done. And I'm looking forward to hearing from our witnesses about just what kind
of work we can do.
Another issue I know that many people will be raising is the issue of producing flu
vaccine here domestically in the United States, because, God forbid, we have another flu
pandemic. We want to make sure that we can protect our own people.
And so, again, I'm thankful that we have such a distinguished panel today. I
understand that you've brought slides, so we will not be disappointed. It's our job
to -- that you have the tools and the resources to remain on the cutting edge of science,
and I hope today that you can tell us what you need going forward.
With that, I am pleased, filling in in the ranking position is the ranker on the full
committee today, Mr. Walden, for 5 minutes.
[The prepared statement of Ms. DeGette follows:]
******** COMMITTEE INSERT ********
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Mr. Walden. Well, thank you, Chair DeGette, we appreciate the hearing today.
As you've said, this is a longstanding bipartisan tradition of this committee to check in
ahead of flu season and find out where we stand and continue to support innovation in
this space and other medical device space and prescription drug space and the whole
thing. When we're trying to find cures for diseases, we're all on board.
So every year millions of Americans put themselves at an increased risk of getting
the flu because they don't get the flu vaccine. Just for the record, I have. I'm not a big
guy on shots, but I -- you know, I do it every year, and I'm glad I do. They also -- people
who don't, though, are increasing the risk for the individuals who cannot be vaccinated,
including young children who are not old enough to get the flu vaccine, will get the flu.
So if you've not gotten the flu vaccine yet this year -- I spent a night or two in a Holiday
Inn, so I'm going to play doctor here -- go get the flu vaccine. If they shouldn't, I'll let
our panel of real live doctors counter me on that, but I think that would be your counsel
to all of us as well.
If you think you may have the flu, please go see your doctor. There are antivirals
available to reduce the symptoms you experience with the flu and short-lived duration of
the flu. Great advances there.
Our senior citizens are the group at greatest risk of serious flu-related
complications. According to the Centers for Disease Control and Prevention, people 65
years of age and older account for about 70 to 85 percent of seasonal flu-related deaths
in recent years, and between 50 to 70 percent of seasonal flu-related hospitalizations.
Seniors can get the regular flu shot or one of the two flu shots that are specifically
designed for people 65 years of age or older -- the high dose flu vaccine and the
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
adjuvanted -- I'll get that -- flu vaccine.
I, along with some of my fellow Republican members of the committee, sent a
letter to the director of the CDC last February about improving flu vaccination coverage
for seniors. We asked whether a preferential recommendation from CDC's Advisory
Committee on Immunization Practices, ACIP, for vaccinating adults 65 years of age and
older with a high dose or an adjuvanted influenza vaccine could reduce deaths and
hospitalizations or even improve vaccination coverage. CDC told us they did not believe
that there was adequate information on these vaccines to rise to a level of ACIP making a
preferential recommendation.
Given what appears to be substantial evidence substantiating superior
effectiveness for seniors with each of these alternatives compared to the standard-dose
flu vaccine, and the preferential recommendations from other respected foreign health
authorities for one of these alternatives, I do want to explore the reasons for CDC's
hesitancy about supporting preferential recommendation when it appears there's real
reason to believe it could help save lives.
I'm also looking forward to hearing more about research efforts to improve the flu
vaccine and hopefully develop a universal flu vaccine. A universal flu vaccine would
provide long-lasting protection against multiple seasonal and pandemic flu viruses, and I
expect Dr. Fauci will update us on HHS' progress in implementing the strategic plan for a
universal influenza vaccine that was first published in February of 2018.
Now, the President's recent executive order promotes the development of better
flu vaccines, and I support its emphasis on the need to modernize the manufacturing
process for the flu vaccine. The current egg-based manufacturing process that's used
for most flu vaccine doses administered in the United States takes about 22 to 24 weeks
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
to produce the flu vaccine.
Earlier this year, advisers at the World Health Organization delayed their
recommendations for the H3N2 vaccine strain to include in the flu vaccine this year by a
month. And there were considerable concerns that that delay might adversely affect
the vaccine supply at the beginning of this season. Thankfully, the delay did not impact
the supply.
So I look forward to today's discussion. I hope to hear more about faster and
more scaleable manufacturing platforms, the role of antiviral drugs to mitigate the
severity of the flu, and the concern over possible drug-resistant flu strains.
With that, I would yield the balance of my time to the gentlelady from Indiana,
Mrs. Brooks.
Mrs. Brooks. Thank you, Mr. Walden.
It's been over a hundred years since the 1918 pandemic flu killed millions of
people around the world, and actually, 675,000 Americans lost their lives then. Last flu
season, and I think most people don't realize, 61,000 Americans lost their lives, including
a hundred Hoosiers.
Although the development of vaccines and drugs is a challenging process, it is so
important that we continue to take action to modernize our influenza vaccines in this
country.
This committee, led by this committee, we passed PAHPA into law earlier this
summer, the reauthorization of PAHPA. It established a pandemic influenza program as
well as an emerging infectious disease program at BARDA to deal with known and
unknown threats. The research funded by BARDA has already significantly expanded
our domestic vaccine production capacity from the ability to produce just 60 million doses
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
of antigen influenza to the ability to produce more than 600 million doses. And with
PAHPA, it supports the increase of our manufacturing capacity and our stockpile medical
countermeasures, but we have much work left to do.
I want to thank all the incredible witnesses here today for your expertise. You
and your teams are the ones that are going to ensure that our Nation is better prepared
for pandemic flu. I look forward to hearing from our witnesses.
I yield back.
Mr. Walden. And I yield back.
[The prepared statement of Mr. Walden follows:]
******** COMMITTEE INSERT ********
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Ms. DeGette. The chair now recognizes the chairman of the full committee,
Mr. Pallone, for 5 minutes for purposes of an opening statement.
The Chairman. Thank you, Chairwoman DeGette.
Every year, influenza causes millions of illnesses, hundreds of thousands of
hospitalizations, and tens of thousands of deaths across the United States. Last year,
more than a hundred children died as a result of this preventable and treatable disease,
and while we're still in the early months of this year's flu season, it has already resulted in
the deaths of five children.
Today, we're continuing this committee's long history of examining flu
preparedness and response, and I want to thank Chairwoman DeGette in particular
because I know that she annually -- pretty much annually has these hearings because she
thinks it's very important. And I do want to also thank our ranking member of the full
committee, Mr. Walden, for pointing out, as an example, that he had his flu shot, and I
had mine too, because I think we do have to serve as an example.
The flu is one of the many preventable infectious diseases that threaten public
health. We know that seasonal flu is particularly challenging to address. Flu viruses
are mutating and changing constantly, and we do not yet have the ability to predict how
severe flu season will be, when it will peak, or what flu strains will dominate. We also
have a lot of questions about why the flu vaccine is more effective for some people and
how someone's health status may affect the body's immune response.
I've been encouraged by recent efforts at the National Institutes of Health to study
these issues with the goal of producing a universal flu vaccine that is effective against a
broader range of flu strains. I'm also encouraged by the ongoing research supported by
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
the Biomedical Advanced Research and Development Authority, or BARDA, and the
ongoing leadership in coordination among all of the agencies testifying before us today.
These efforts are vitally important.
While we wait for the results of this research, it's still critical that we continue to
stress the importance of getting vaccinated every year. Thankfully, cost should no
longer be a barrier for anyone to receive their annual flu vaccine. Thanks to the
Affordable Care Act, flu and other immunizations are required to be covered by health
insurance at no cost to the patient. The Vaccines for Children Program has also
provided free vaccinations for eligible children for nearly 25 years.
Annual flu vaccination is the best method for preventing flu and its potentially
severe complications. This is true even when the flu vaccine is less effective for various
strains. For example, during the 2017-2018 season, the effectiveness of that year's flu
vaccine was estimated at 40 percent overall. Yet the Centers for Disease Control and
Prevention estimated that it still prevented over 6 million illnesses, 91,000
hospitalizations, and 5,700 deaths.
Vaccinating yourself not only increases the odds that you won't get sick this
season, but also protects everyone you come in contact with. And this is particularly
important for those more vulnerable to the flu and its symptoms, such as people with
chronic health conditions, older parents, or a baby niece or nephew.
And all of this demonstrates the importance of getting a flu shot, but
unfortunately, 55 percent of adults were not vaccinated against the flu last season. So I
look forward to hearing from the CDC about its communications and outreach strategies
to increase the rates in the future.
And I know that one of the issues continues to be public confidence in vaccines,
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
but it's critical that we continue to get the word out that vaccines are safe. While
harmful misinformation campaigns continue to proliferate online and in communities
across the country, the agencies must continue to spread the message of vaccine safety.
And we also have to continue to improve our vaccine manufacturing process to make flu
vaccines even more effective and our ability to treat patients if they do come down with
the flu.
So again, I thank our witnesses for joining us, for the critical leadership role your
agencies play in our Nation's flu preparedness and response efforts. And again, thank
you, Chairwoman DeGette.
I yield back.
[The prepared statement of Chairman Pallone follows:]
******** COMMITTEE INSERT ********
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Ms. DeGette. The gentleman yields back.
The chair now recognizes and welcomes the chair -- the ranking member of the
subcommittee, Mr. Guthrie, for 5 minutes.
Mr. Guthrie. Thank you very much. Thank you, Chair DeGette, for holding this
hearing on such an important issue.
This committee has a long history of conducting oversight of the Federal
Government's response to the seasonal flu. The flu is a leading cause of death in the
United States. Thousands of Americans die from flu every year, and hundreds of
thousands of Americans are hospitalized.
Last flu season alone, the CDC estimates that up to 42.9 million people got sick
with the flu, up to 647,000 individuals were hospitalized, and up to 61,200 individuals
died from the flu. Individuals 65 years and older accounted for 90 percent of the deaths
and 70 percent of the hospitalizations for the 2017-2018 flu season.
In light of this tremendous burden on our seniors, in February of this year, I, along
with Republican leaders Walden and Dr. Burgess, wrote to the CDC director about
whether the CDC is doing enough to improve flu vaccine coverage and to promote
high-dose and adjuvanted flu vaccines. I practiced that word twice, and I still couldn't
get it out.
While we examine how to improve the response to seasonal flu, we know the best
way to prevent getting the seasonal flu is to get vaccinated each season. If you have not
already gotten your flu vaccine this season, please go get your flu vaccine today.
Although the flu vaccine does not have the level of effectiveness of other
well-known vaccines, it is absolutely better than doing nothing. The flu vaccine saves
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
thousands of lives each year. The flu vaccine also helps reduce severe outcomes when
someone does become sick with the flu.
According to CDC data, about 80 percent of the flu associated with deaths in
children have occurred in children who were not vaccinated. Moreover, a 2017 study
showed that the flu vaccine also reduces severe outcomes in hospitalized patients.
I have questions today on how we can continue to improve the flu vaccine.
Preliminary CDC data shows that the seasonal flu vaccine was only 29 percent effective
for the 2018-2019, the lowest it has been in a decade. For more than 70 years, most flu
vaccines administered in the United States have been made through the egg-based
manufacturing process. We have seen some innovation over the last decade, however,
with the introduction of the new manufacturing technologies, using a cell or recombinant
DNA technology. Most of the flu vaccine doses distributed in the United States are still
manufactured using egg-based process.
Indeed, the CDC estimates that about 82 percent of the projected vaccine supply
produced for the 2019-2020 flu season will be produced using egg-based manufacturing
technology, while the remaining vaccine will be produced using the cell-based and
recombinant technology.
During the hearing on March 2018, Dr. Rick Bright, the HHS Deputy Secretary for
Preparedness and Response, testified that we can improve the effectiveness of a vaccine
in four ways: Expand domestic capacity for the cell-based and recombinant-based
technologies enhances the effectiveness use of flu vaccines; and the addition of adjuvants
or higher doses of antigen; conduct clinical trials to expand vaccine in all age groups; and
continue to modernize the vaccine production processes for speed and flexibility.
At that hearing, Dr. Bright noted that cell-based and recombinant-based
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
technologies offer greater speed and flexibility than the traditional egg-based
manufacturing process. And some studies have shown that they may also be more
effective than egg-based vaccines.
For these reasons, I was pleased to see the President make modernizing and
improving influenza vaccines a top priority through his executive order on September 19,
2019. Modernizing flu vaccines will help protect lives through prevention and promote
public health and national security.
Pandemic and seasonal flu are interdependent, and our approaches to seasonal
and pandemic influenza are inextricably interwoven. What we do in one area directly
impacts the other area. For example, when we expanded our domestic manufacturing
capacity for pandemic response, manufacturers then also had the capacity to include an
additional flu strain in the seasonal vaccine, moving from three-strain to four-strain
seasonal vaccines for better coverage.
I appreciate the administration's commitment to improving our flu preparedness.
I welcome all of today's witnesses, and look forward to today's discussion about how we
can keep Americans healthy during flu season and improve our Federal response to both
pandemic and seasonal flu.
And I yield back.
[The prepared statement of Mr. Guthrie follows:]
******** COMMITTEE INSERT ********
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Ms. DeGette. I thank the gentleman.
I ask unanimous consent that members' written opening statements be made part
of the record.
Without objection, so ordered.
I now want to introduce the witnesses for today's hearing. Dr. Nancy
Messonnier, who's the director of the National Center for Immunization and Respiratory
Diseases, Centers for Disease Control and Prevention. Welcome. Dr. Anthony Fauci,
director, National Institute of Allergy and Infectious Diseases, National Institutes of
Health; Dr. Robert Kadlec, Assistant Secretary for Preparedness at U.S. Department of
Health and Human Services; and Dr. Peter Marks, director, Center for Biologics Evaluation
and Research, U.S. Food and Drug Administration.
I want to thank again, I thank all of you for coming before the committee. You're
aware, I know, that the committee's holding an investigative hearing, and when we do so,
we have the practice of taking testimony under oath.
Does anyone have an objection to testifying under oath today?
The witnesses have all responded no.
The chair then advises you, under the rules of the House and the rules of the
committee, you're entitled to be accompanied by counsel.
Does any of you wish to be accompanied by counsel?
Let the record reflect the witnesses have responded no.
If you would please rise and raise your right hand so you may be sworn in.
[Witnesses sworn.]
Ms. DeGette. Let the record reflect that the witnesses have responded
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
affirmatively. And you're now under oath and subject to the penalties set forth in title
18, section 1001 of the U.S. Code.
The chair will now recognize our witnesses for a 5-minute summary of their
written statement. In front of you is the microphone and a series of lights. The timer
counts down your time, and the red light turns on when your 5 minutes has come to an
end.
Dr. Messonnier, you're now recognized for 5 minutes.
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
TESTIMONY OF NANCY MESSONNIER, M.D. (CAPT, USPHS, RET), DIRECTOR, NATIONAL
CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES, CENTERS FOR DISEASE
CONTROL AND PREVENTION; ANTHONY S. FAUCI, M.D., DIRECTOR, NATIONAL
INSTITUTE FOR ALLERGY AND INFECTIOUS DISEASES, NATIONAL INSTITUTES OF HEALTH;
ROBERT P. KADLEC, M.D., M.T.M.&H., M.S., ASSISTANT SECRETARY FOR PREPAREDNESS
AND RESPONSE, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES; AND PETER
MARKS, M.D., PH.D., DIRECTOR, CENTER FOR BIOLOGICS EVALUATION AND RESEARCH,
U.S. FOOD AND DRUG ADMINISTRATION
TESTIMONY OF NANCY MESSONNIER, M.D.
Dr. Messonnier. Good morning, Chairman DeGette, Ranking Member Guthrie,
and members of the committee. I'm Dr. Nancy Messonnier, director of the National
Center for Immunization and Respiratory Diseases at CDC. And I want to thank the
committee for the opportunity to discuss CDC's work to protect Americans from
influenza.
Influenza is a serious and ongoing public health threat. Each year, millions of
Americans get sick, hundreds of thousands require hospitalization, and tens of thousands
die. The one certainty with influenza is that it is unpredictable. The virus is constantly
changing and generating new flu strains that can lead to more severe flu seasons and
devastating pandemics.
These changes have also allowed the virus to evade existing human immunity and
require us to develop a new vaccine every single year. CDC recommends an annual flu
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
vaccine for everyone 6 months of age and older. Influenza vaccination remains the
single best way for Americans to protect themselves from the flu.
The 2019-2020 flu season has officially begun. National levels of influenza-like
illness have been increasing for nearly a month, with the highest activity in the South and
the West. Despite the significant benefits, the effectiveness of the flu vaccine and the
number of Americans being vaccinated are not optimal. That's why we at CDC are
working with our Federal colleagues to use cutting-edge science to make influenza
vaccines better and ensuring providers and the public are choosing to vaccinate with
confidence. This is a complicated multiyear process that must be both stepwise and
iterative.
Under the recently announced executive order to modernize influenza vaccines,
CDC will work with our partners to promote new technologies to improve vaccine
manufacturing and effectiveness.
While the long-lasting broadly protective universal vaccines that Dr. Fauci will talk
about are the ultimate goal for flu prevention, these vaccines are still years away. In the
nearer term, we can save millions of Americans from the flu by making incremental
improvements to vaccines. If we increase vaccine effectiveness by just 5 percent, we
can prevent over 17,000 additional hospitalizations in a single year.
Despite overwhelming and consistent scientific evidence that flu vaccines are safe
and effective, nearly 40 percent of children and over half of adults did not receive their flu
vaccine last season.
Flu vaccines are very safe. During the 2018 to 2019 flu season, nearly 170 million
doses of flu vaccines were distributed nationwide. Of these, less than 0.01 percent of
those receiving a vaccine reported a potential adverse event. Injection site reactions
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
were the most commonly reported event.
CDC has a central role in every part of influenza vaccine development and
administration. Over the last decade, CDC has significantly improved worldwide
surveillance and characterization of influenza viruses. Global epidemiological and
biological data is the foundation of the influenza vaccine virus selection and development
process. We develop diagnostic assays for public health laboratories in the United
States and globally, and we ship them around the world.
CDC uses next-generation sequencing to gather and analyze genomic data and
share this data with other stakeholders. Genomic data help us make better decisions
about what goes in each year's flu vaccine and also help us to evaluate viruses for their
pandemic potential.
CDC has invested in each State public health department to have automated real
time electronic laboratory reporting of influenza test results to CDC using cloud-based
messaging. CDC has supported manufacturing innovations by developing candidate
vaccine viruses for the cell-based vaccine and providing genomic sequences used to make
the recombinant protein vaccine.
Genomic sequencing equipment, which once filled the room, now fits in the palm
of your hand. We now have a mobile mini laboratory that can be taken on a plane as a
carry-on and set up almost anywhere around the world. Both cell and recombinant
vaccines have the potential to be manufactured more quickly and may be more effective
than traditional vaccines that are grown in eggs.
CDC was the first to establish a national system for the routine monitoring of
influenza vaccine effectiveness, and we're currently expanding this network to add new
immunity tests. This system provides critical information for manufacturers and
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
researchers in developing enhanced vaccines by collecting specific data about how well
the vaccine works each season in each population. CDC will continue to innovate to
make incremental improvements in vaccine effectiveness and vaccine coverage.
This week is National Influenza Vaccination Week, and it is a great opportunity to
remind all of you to protect yourselves and your family by making sure that you and your
families get the annual flu vaccine.
Thank you for the opportunity to speak, and I'm happy to take questions.
[The prepared statement of Dr. Messonnier follows:]
******** INSERT 1-1 ********
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Ms. DeGette. Thank you so much, Doctor.
And now, Dr. Fauci, you're recognized for 5 minutes.
TESTIMONY OF ANTHONY S. FAUCI, M.D.
Dr. Fauci. Chairperson DeGette, Ranking Member Guthrie, members of the
committee, thank you for giving me the opportunity to speak to you today about the role
of the National Institutes of Health in their research in addressing seasonal and pandemic
flu.
If I could have the slide up, please.
As you've heard, and many of you have mentioned, the current seasonal influenza
vaccines are not consistently effective, but I want to underscore what several people have
said today, that it doesn't really matters if it's a hundred percent, 50 percent, or 20
percent, it is always, always better to get vaccinated than not.
Yet we need to do better. Both the seasonal flu and the fact that pandemics do
occur -- we have experience that tell us it happens and will happen again. In addition,
we tend to be able to chase after potential pandemics, like the H5N1, the H7N9.
This is a paper that we wrote just a little while ago, emphasizing the point that
I'm -- oops, it disappeared. Sorry, there you go -- that we really need to do better. We
need to do better in two aspects. We need to improve seasonal influenza vaccines, we
need to prepare for pandemics, and we do need a universal vaccine. And that's what I
want to talk about over the next couple of minutes.
As was mentioned just a while ago, we put together a strategic plan and a
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
research agenda to develop a universal influenza vaccine, and published this in February
of 2018. This plan is what we call an iterative plan. By "iterative," meaning it would be
a stepwise process. We are not going to get a universal flu vaccine next month or next
year.
This particular slide shows what we call the two major groups of influenza
vaccines -- influenza A vaccines -- not vaccines, but viruses.
The first group, as you see there, contains a number of influenza As, including H1
and the prepandemic H5. Group 2 contains H3 and the prepandemic H7. When we
start developing a universal influenza vaccine, we will start with getting H3N2 or H1N1, all
of the iterations, and then we'll move to the next one. And that's what that pyramid,
that triangle there is on the right.
The first is a highly specific vaccine, what we have today, what we're giving to
people in today's vaccine. As you go down, you get broader coverage. That's what we
mean when we say a universal influenza vaccine.
You mentioned the issue of egg-based and the vicissitudes associated with that.
These are various vaccine platforms. By "platforms" we mean a certain mechanism
whereby we have a vaccine that does not require growing the egg -- growing the virus in
eggs or even in cells. It's the recombinant DNA technology that you just mentioned.
Let me give you an example of how we're using that to develop a universal flu
vaccine. This is a picture of the influenza virus on the left. On the right is a blowup of
the hemagglutinin protein on the surface of that virus. As you can see here, there are
two components of it: a head and a stem. The vaccine induces a response
predominantly against the head, which is good news, because if it works, it protects you.
However, unfortunately, that particular component of the protein mutates
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
readily. So from season to season, it tends to drift. And that's the reason why all of us
should get a vaccine every single year. When it changes a lot, we call that a shift, and
that's when you get a pandemic. But note that the red dots, which mean mutations, are
very few on the stem. That does not change very much.
And what investigators have done over the last few years is recognize that if you,
for example -- and this is just one approach to a universal flu vaccine -- if you cut off the
head and take that stem and put it on a nanoparticle, which is one of those platforms that
I mentioned -- and I have an example of one of them blown up 4 million times. This is
the first example of a true universal flu vaccine that are directed against the group 1.
And this was just put into clinical trial last spring, a phase 1 trial. It is currently in phase
1. We're asking about safety and does it induce a good immune response.
Next year, we will try to cover the group 2. And I hope that as you continue to
have these annual hearings, we'll be able to, year after year, come back to you and talk to
you about the progress of going from the top of that pyramid all the way down to a true
universal influenza vaccine.
Thank you.
[The prepared statement of Dr. Fauci follows:]
******** INSERT 1-2 ********
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Ms. DeGette. Thank you so much, Dr. Fauci.
Dr. Kadlec, now you're recognized for 5 minutes.
TESTIMONY OF ROBERT P. KADLEC, M.D.
Dr. Kadlec. Thank you, Chairwoman DeGette, Ranking Member Guthrie, and
distinguished members of the subcommittee. Thank you for your continued
commitment to flu preparedness and the opportunity to testify on our efforts to develop
and rapidly manufacture effective medical countermeasures to treat influenza.
As noted, influenza is a serious threat to human health and poses a significant
national security risk. Annually seasonal flu leads to hundreds of thousands of
hospitalizations, tens of thousands of deaths, and costs $30 billion a year in lost
productivity and healthcare costs. An influenza pandemic would be even worse, killing
hundreds of thousands of Americans, costing up to $3.8 trillion.
Mitigating both seasonal and pandemic influenza is critical to saving lives,
protecting Americans, and reducing the economic and healthcare burdens that result.
Before going further, I want to take a moment to thank you and your staff who
worked on passing the Pandemic All-Hazard Preparedness and Advancing Innovation Act
of 2019. It strengthens public health and readiness and healthcare readiness, bolsters
response and recovery programs and increases transparency.
Specific and relevant to this hearing, it authorized an annual appropriation for
pandemic influenza that will ultimately enhance the confidence of private partners to
invest in research, development, and manufacturing activities.
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
We also appreciate the past congressional supplemental appropriations for
pandemic influenza preparedness, with a 2005, 2006, and 2009 supplemental
appropriations, we invested in new vaccines, antivirals, domestic manufacturing, and
enhanced stockpiling. Continued effort and support and funding remains critical,
however.
ASPR's role in pandemic influenza preparedness has defined multiple policy
documents. The 2017 HHS Pandemic Influenza Plan outlines ASPR's initiatives to
prevent, control, and mitigate the effects of the influenza virus to humans. More
recently, in September of this year, the White House released an executive order on
pandemic influenza preparedness. This EO identifies specific activities, many of which
ASPR's already supporting with BARDA, to strengthen preparedness efforts.
Turning to preparedness initiatives, thanks to BARDA's investments, we've
supported the development and approval of 23 influenza-related vaccines, antiviral drugs,
devices, and diagnostics. Two significant items related to vaccine development is that
now there is a licensed, cell-based influenza vaccine that can be administered to
individuals 4 years and older, and a licensed recombinant DNA influenza vaccine available
for persons 18 and older.
To enhance overall vaccine supply, we've supported development and licensure of
adjuvanted and influenza vaccines, and during a pandemic, using adjuvants increase not
only the limited vaccine supplies to protect more people, but do so faster.
To treat persons infected with influenza, we're also developing antiviral drugs.
ASPR and BARDA has funded nine novel antiviral advanced development projects since
2007. To better detect the emergence of influenza, we're supporting the development
of in-home and wearable diagnostics to enable patients to take responsible actions
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
towards earlier treatment to reduce the severity of the illness and nonpharmaceutical
approaches like staying home to prevent spread of the disease.
While medical countermeasures will aid in the response and potentially limit the
spread, there will be a strain on our healthcare infrastructure. Since 2002, investments
administered through ASPR's Hospital Preparedness Program have improved individual
healthcare entities' preparedness and have built a better coordinated system.
Beginning in 2018, ASPR has supported regional partnerships to enhance
capabilities above what exists at the local coalition level. The intended goal is to enable
multiple healthcare systems to leverage assets and support one another when needed.
A second issue that impacts response capabilities is our dependence on medical
supplies, active pharmaceutical ingredients, and raw materials from overseas. When
considering the global challenges of a pandemic, this dependence would become a
matter of national security. ASPR is now incorporating new technologies to support
innovation for preparedness and response. An example is alternative administration
approaches such as microneedle patches that deliver vaccine through the skin that could
limit our dependence on imported needles and syringes and allow for faster delivery and
administration of vaccine. We'll continue to look for other innovative alternatives to
address our reliance on foreign supplies.
An influenza pandemic poses a significant threat to national security that could
result in a significant loss of life, negatively impact the economy, and place a tremendous
strain on our healthcare infrastructure. Continued support from Congress is critical to
push the needle forward to best protect and respond to emerging threats.
Thank you for your time, and I look forward to discussing how we can continue to
work together on this important issue, and I'll be happy to answer any questions you may
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
have.
[The prepared statement of Dr. Kadlec follows:]
******** INSERT 1-3 ********
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Ms. DeGette. Thank you, Doctor.
Dr. Marks, now I'll recognize you for 5 minutes for an opening statement.
TESTIMONY OF PETER MARKS, M.D.
Dr. Marks. Thank you, Chair DeGette, Ranking Member Guthrie, distinguished
members of the subcommittee. I'm Peter Marks, director of the Center for Biologics
Evaluation and Research at the Food and Drug Administration. Thank you for the
opportunity --
Ms. DeGette. Dr. Marks, can you just move the microphone a little closer?
Thanks.
Dr. Marks. Sorry.
Thank you for the opportunity to describe FDA's efforts, in close coordination and
collaboration with its Federal partners, to ensure the development, approval, and
availability of critical safe and effective medical products to address seasonal and
pandemic influenza.
These products for influenza include drugs such as antiviral agents for its
prevention and treatment, biologics including vaccine for prevention across the age
spectrum, and devices for rapid diagnosis and supportive care.
FDA's involvement in these products spans the entire product life cycle, and the
agency makes use of all of its available regulatory tools and expedited programs,
including those provided by Congress, as appropriate, to help advance products critical
for public health through toward approval.
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Following approval, the agency monitors the safety of these products through
post-market surveillance. Americans can rely on the fact that in approving a medical
product, FDA has determined that it is both safe and effective. The confidence in safety
and effectiveness can be particularly important in combatting increased vaccine hesitancy
which can undermine the public health benefits of vaccination.
Influenza viruses continually undergo changes in their genetic makeup. These
changes can occur from one season to the next. They can also occur during influenza
season. Unlike other vaccines, the composition of influenza vaccines must be updated
annually so that they're effective against the predominant circulating virus that's
anticipated in the upcoming influenza season.
For the 2019-2020 season, there have been more than 160 million doses of
influenza vaccine produced for use in the United States, and manufacturing demands for
influenza vaccines are substantial. No other vaccine is produced, FDA-approved, and
distributed every year across the Nation within an approximately 6-month timeframe.
Manufacturing of the antigens to be included in the vaccines usually occurs
between December and May of each year. FDA then approves the updated seasonal
influenza vaccines by the end of July, and in parallel with vaccine manufacturing, FDA
develops and calibrates reagents that are provided to vaccine manufacturers and our
regulatory counterparts across the globe. Manufacturers and the FDA use these
reagents to test the vaccines for potency and identity before FDA provides approval of
the new formulation of the licensed seasonal influenza vaccines for distribution in the
United States.
Every year, FDA begins working with manufacturers at the earliest stages of
influenza vaccine development, and we continue to assist them throughout the
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
production phase. During this period, we engage with companies on technical and
manufacturing issues and conduct facility inspections, as warranted, to ensure
compliance with current good manufacturing practices. The rigorous timelines currently
required for vaccine production, including strain selection, reagent preparation,
manufacturing of vaccine components, and formulation, fill, and distribution of the final
product leave little room for error or for changes in vaccine composition after the initial
strain selection process.
On the horizon are advances in manufacturing, as well as the adoption of different
technologies for the production of antigen that could help compress the timeline for the
production process and provide greater predictability. Certain technologies could offer
more opportunity to adjust the composition of the vaccine closer in time to influenza
season should a new influenza strain emerge after production has already begun.
In this regard, FDA scientists are collaborating with others to develop such needed
advanced manufacturing technologies to more efficiently produce influenza virus or
influenza antigen. The development adoption of such advanced manufacturing
technologies has the potential to address the need for maximally efficient, agile, and
flexible manufacture of both current and next-generation influenza vaccines produced
according to the FDA's high standards for safety and effectiveness on which the American
public relies.
Collaboration across the Federal Government is essential to meeting these
challenges, and FDA looks forward to collaborating with BARDA, CDC, and NIH to
implement the recent executive order on modernizing influenza vaccines and to further
accelerating the adoption of improved influenza vaccine technologies.
As we continue to invest in the future of manufacturing and vaccine technology,
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
we also need to remember the importance of simply ensuring that more people are
vaccinated, so please get your flu vaccine. And we also must work hard to ensure that
products used to treat influenza, including antivirals and intravenous saline, are available
and that we take steps to prevent and address shortages. As always, FDA remains
committed to communicating and sharing updates with the public about all aspects of our
flu response.
I look forward to answering your questions today. Thank you.
[The prepared statement of Dr. Marks follows:]
******** INSERT 1-4 ********
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Ms. DeGette. Thank you, Doctor.
Apparently, they were getting ready for the Energy and Commerce holiday party
early and they turned the lights down. They thought we should illuminate this
important issue by turning the lights back up.
Okay. Now it's time for the members to ask questions, and the chair will
recognize herself for 5 minutes.
And I just want to say it's really easy to forget about the dangers that even
seasonal flu can pose. We worry about pandemic flu, of course -- I was telling
Mr. Guthrie that keeps me up at night -- but the regular flu that occurs every year, people
just dismiss it as like a cold or a stomach bug, but we shouldn't lose sight of the fact that
the flu is consistently one of the 10 leading causes of death in the United States, and it
leads to millions of illnesses every year. As many as 61,200 people died of seasonal flu
just last year.
And so, Dr. Messonnier, I wanted to ask you, briefly remind us why the seasonal
flu provides such a danger to public health.
Dr. Messonnier. Sure, thank you. And I think that's a really great point, that
people dismiss the flu and confuse it with common colds that are also circulating this
year. Anybody who's had influenza can tell you that it's nothing like that, and it can be
incredibly serious.
The numbers for last year are preliminary, but I think they're a great place to start.
Last year's season was one of the longest seasons on record, and our estimates are 40
million cases, 19 million office visits, 576,000 hospitalizations, 45,000 deaths, and
importantly, 143 children died last year from influenza, and that's really a startling
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
number.
Ms. DeGette. Thank you.
Dr. Fauci, in my opening, and I know you referred to the fact that this virus
mutates, sometimes even within one flu system -- or flu season. Why is it so critical for
us to maintain vigilance in protecting against this really unpredictable virus?
Dr. Fauci. Well, I think you just said it, the fact that it is unpredictable means we
need to be prepared, and the best way to be prepared from season to season is to
develop a vaccine as closely matched to what you would predict the dominant circulating
strain would be. In addition, there are other public health measures in addition that
complement vaccine, such as treatment for influenza, particularly among those
individuals who are at high risk for complications, such as the very young, the elderly,
those with underlying conditions, pregnant women, et cetera.
We need to also do things that are public health measures. For example, if you
do have the flu or your child has the flu, don't go to work, don't go to school. Make sure
you don't spread it around the community.
Ms. DeGette. Right.
Dr. Kadlec, what keeps you up at night when you think about preparedness for the
next flu -- big flu outbreak?
Dr. Kadlec. Pardon me. Thank you, ma'am, I appreciate the question. I mean,
I sleep like a baby, I wake up every 2 hours screaming, but --
Ms. DeGette. Like me.
Dr. Kadlec. Yeah. But I think the key thing here is a pandemic. Quite frankly, I
have unique background on this committee or this dais to have served 2 years on the
Senate Intelligence Committee and looked at the many threats that face the United
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
States. But there is no singular threat that could devastate our country through our
health and our economy and our social institutions than pandemic influenza.
Ms. DeGette. Yeah.
Dr. Kadlec. And we had four during the last century. And even though we've
had a mild one in this first century, I think the risk is that we'll have another severe one,
and that would devastate our country.
Ms. DeGette. And I know this panel has a lot more questions about that, but I'll
throw that back to you, Dr. Fauci. I know this is why -- one of the reasons why it's so
important that we continue to innovate and to advance the vaccines. What can
Congress do -- what can Congress continue to do to help in these efforts to modernize
and streamline the flu vaccine?
Dr. Fauci. Well, Madam Chairperson, what you can do is what you have been
doing, and it really is very important. And all of us feel very strongly in a positive way
how this committee continues to come back each year and emphasize publicly the
importance of this.
With regard to support, the Congress has been extremely supportive of the
research efforts at the NIH, as well as the work that the CDC and other agencies do. So
my direct answer to your question is just keep it up, please.
Ms. DeGette. Okay. All right. Just because you said so.
Dr. Messonnier, I know that the chairman is going to ask you about what CDC is
doing for public awareness, but maybe you can start giving me a brief answer to that.
Dr. Messonnier. Thank you. You know, Dr. Fauci and I were here previously
talking in general about vaccines and the concerns about vaccine hesitancy in the United
States. For flu, we have both concern from the public about the safety of vaccines, and
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
we need to reassure the public as well as emphasize the importance of their providers
educating their patients about the safety and effectiveness of flu vaccine. But actually,
if you ask people why they don't get the flu vaccine, what's different than other vaccines
is, another reason that they really reflect on this, that they don't believe the flu vaccine
works.
Ms. DeGette. All right.
Dr. Messonnier. I think we have to do a better job at educating people that,
even if you can still get the flu with the flu vaccine, the flu is milder, and it can prevent
hospitalizations and deaths. So it's worth getting it even for a year when it's not a
great --
Ms. DeGette. Thank you.
The chair now recognizes the ranking member for 5 minutes for questioning.
Mr. Guthrie. Thank you.
I was going through trying to figure out where you've already answered some of
my questions so we're all kind of on the same page on this area, which is great, but
I'll -- so I may be repetitive, but it's important to repeat sometimes some of these things.
So, Dr. Kadlec, the September 19 executive order directs HHS to estimate the cost
of expanding and diversifying domestic vaccine manufacturing capacity using innovative,
faster, and more scaleable technologies. So putting that into real words, why is it
important for us to improve our domestic vaccine manufacturing capacity for flu? And
what faster and more scaleable technology would need to be used to expand and to
diversify domestic capacity?
Dr. Kadlec. Well, thank you for your question, sir. And I think very simply is,
the reason why domestic manufacturing is so critical, particularly for pandemics, is if
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
there's a pandemic, everybody will be taking care of themselves. And so the fact if
we're reliant on foreign suppliers for vaccines or anything else, we're likely to be at the
end of that line, because they're going to be taking care of that first.
The second issue is, quite frankly, sir, is there are technologies that exist today and
some that Dr. Fauci's working on, like messenger RNA that will permit faster and more
better matched vaccines to basically prevent flu, both seasonal and pandemic.
And specifically because of Congress' investments in the past, through the
previous supplementals, we've developed two new vaccine technologies: One,
recombinant cell culture, and the other one is recombinant DNA vaccines. And those
are two very good and faster methods for producing. We have yet to know whether
they are more effective than eggs. We believe so, but I think Dr. Messonnier can
probably talk about some of the work that is ongoing in research, as well as Dr. Fauci to
that. But those are two areas that I think we have leveraged it.
Unfortunately, those technologies do not have the capacity yet to overtake what
we do with the egg-based flu vaccines.
Mr. Guthrie. Okay. Thank you.
And again, Dr. Fauci, in your statement, you noticed that alignment with the goals
of the executive order, the National Institute of Allergy and Infectious Diseases is
conducting and supporting research to develop state-of-the-art vaccine platform
technologies that could be used to develop universal flu vaccines as well as improve the
speed and agility of the flu vaccine manufacturing process.
So the question is, how are the vaccine platform technologies that the NIAID is
currently researching different from flu vaccine production strategies?
Dr. Fauci. Well, the platforms that I showed on one of those slides are each
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
different way. All of them have a basis in recombinant DNA technology, but the critical
issue about that is you don't need to grow the virus. And that is important, because
when you grow the virus, it takes 5 to 6 months from the time you grow it, the way we do
in eggs today and some in cells, and a number of things can happen when you do that.
You can make a choice in February or March that this is the strain that you want to aim
for for the following season, but by the time you get to the following season, it might
have changed, number one.
Number two, there have been examples of when you put the virus in the egg, the
virus tends to adapt to grow better in the egg, and it mutates. It's an RNA virus and it
mutates readily. Most of those mutations don't mean anything. But every once in a
while, it mutates to the point that it actually changes the virus enough that it's different
from what you originally put in.
So all of the platforms, be they recombinant DNA, messenger RNA, DNA,
nanoparticles, viral-like particles, vectors, they all are recombinant technologies that
don't require your growing the virus, and that's very important.
Mr. Guthrie. Okay. Thank you very much. Appreciate that. That's good.
So, Dr. Marks, in March, Dr. Gottlieb testified as the commissioner at the time,
using -- said that FDA scientists are using CMS data to look for differences in effectiveness
in those receiving egg-based and cell-based vaccines, as well as differences in
effectiveness in those that receive the standard dose versus a high-dose vaccine and the
adjuvanted flu vaccine. What did CMS and FDA find by analyzing the Medicare data?
And you can use that word if you'd like so we --
Dr. Marks. I thank you very much. The adjuvanted flu vaccines -- it took me
about 4 years of medical school to learn how to pronounce that, so don't worry, it's okay.
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
So thank you for that question.
The FDA's recently finished a study and published a study that was done in
conjunction with Centers for Medicare and Medicaid Services, using their large database.
And they looked at six seasons' worth of standard dose versus high dose influenza
vaccine. And from that, they were able to see that, particularly in the population of
individuals over 85 years old, the high-dose vaccine, season after season, had better
effectiveness, and even in the population over 65, there was a tendency towards better
effectiveness in that population as well.
Mr. Guthrie. Okay. Thank you.
My time is expired. I yield back.
Ms. DeGette. I thank the gentleman.
The chair now recognizes Mr. Ruiz for 5 minutes.
Mr. Ruiz. Thank you, Madam Chair.
Compassionate prevention and care must be available to everyone in this country,
and as has been alluded here, many people have died due to the flu virus. Just about a
year ago, in fact, this Sunday marks 1 year when Jakelin Caal, a 7-year-old girl, died in CBP
custody because she did not have appropriate access to medical care. Whether or not it
was the flu, I don't believe it was, but there has been several children who have died in
CBP custody since then, including some from the flu.
Following Jakelin's death, I visited the place where she had been held, and I was
horrified by the conditions that I witnessed; facilities so crowded you couldn't even see
the floor, bodies on top of one another, especially children with soiled diapers, coughing
on one another. And there wasn't appropriate access to sanitation places to wash their
hands, to bathe. And these are individuals whose immune systems were always down
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
due to the long trek and probably poor nutrition.
And as public health experts, I think you will all agree with me that such conditions
create a breeding ground for a flu outbreak.
Following my visit, I wrote the Humanitarian Standards for Individuals in CBP
Custody Act, which passed the House. It would ensure that individuals in CBP custody
would have access to an initial health screening, to identify high-risk, vulnerable people,
and provide appropriate intervention to prevent children and the elderly and others from
dying. It would also put in place a baseline set of humanitarian public health standards
such as access to clean water, proper sanitation, and personal hygiene.
I am concerned that despite urging from physicians and physician organizations
and the CDC, CBP has refused to administer flu vaccines to protect children and families in
their custody.
Dr. Messonnier, CDC submitted a report regarding its investigation of respiratory
illnesses in U.S. Border Patrol facilities, including findings and recommendations to the
Department of Homeland Security in January, this past January of 2019. And I would
like to submit this report for the record.
Dr. Messonnier, do the children and adults detained in these facilities face
heightened risk of contracting influenza?
Dr. Messonnier. As you've said, crowded conditions tend to be a breeding
ground for respiratory infectious diseases. There's no specific information right now
about the risk at the border compared to elsewhere. But I think it's important to
remember that CDC recommends that everybody age 6 months of age or older --
Mr. Ruiz. Right, everybody.
Dr. Messonnier. -- be vaccinated.
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Mr. Ruiz. However, this report does state that there was higher prevalence of
influenza in December 2018, January 2019, than the national average. So --
Dr. Messonnier. Right. That's right. So --
Mr. Ruiz. -- in this report, it does, in 2019, January 2019, does show that there
was higher. So --
Dr. Messonnier. Yes.
Mr. Ruiz. -- what recommendations does CDC make to DHS specific to influenza
vaccine and other related care for those detained in Border Patrol facilities?
Dr. Messonnier. So as you said, CDC was asked by DHS for technical assistance in
December of 2018 and January of 2019. We gave preliminary recommendations orally
and then issued a written report. And the written report says that as consistent with
our general infection control guidelines, priority should be given to screening and
isolation of ill migrants, early antiviral treatment, and flu vaccination for all staff.
Mr. Ruiz. Great. In fact, I'll read it here, it says: Influenza vaccination should
be implemented at the earliest feasible point of entry to allow maximum protection of
migrant and potentially to reduce transmission in border facilities. Priority groups
should include children aged 6 months through 18 years and pregnant women.
The term "earliest feasible point" is very important here. Are vaccines -- the
success rate of vaccination, is it -- this is an obvious question, but is it more effective
before they contract the influenza virus or after?
Dr. Messonnier. So it's obviously more effective when it's given before.
Mr. Ruiz. Exactly.
Dr. Messonnier. And I would also just point out perhaps that, you know, HHS'
ORR program routinely vaccinates --
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Mr. Ruiz. They do. ORR and ICE does. I'm specifically talking about CBP, and
that's the point I'm making, because oftentimes, they stay there for 8, 14 days, when
overcrowded conditions. So one of the reasons, perhaps they may say, oh, well, we
want to get rid -- move the children or move the individuals to the next facility, but if they
contract the flu vaccine at CBP, then receiving the vaccine at ICE or ORR is not going to be
helpful. So that's why the recommendation was to vaccinate them at the earliest point
of entry at CBP.
And I ran out of time. Thank you.
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
RPTR MERTENS
EDTR HUMKE
[11:27 a.m.]
Ms. DeGette. Without objection, the CDC report is entered into the record.
[The information follows:]
******** COMMITTEE INSERT ********
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Ms. DeGette. The chair now recognizes the gentleman from West Virginia for
5 minutes.
Mr. McKinley. Thank you, Ms. Chairwoman.
I think maybe, Dr. Messonnier, maybe I will focus on you. Did I -- I want to make
sure I heard your answer to the question why aren't -- why aren't more people getting a
vaccine. And I thought your answer was something about the public's concern with its
effectiveness. Am I -- did I state that correctly?
Dr. Messonnier. I think that there are three reasons why people don't get
vaccinated, speaking generally. One is incorrect concern about the safety of the
vaccine. A second is misunderstanding that the vaccine -- about vaccine effectiveness,
and the third, frankly, is access. It --
Mr. McKinley. Okay. Let me focus more on that third because I think the first
two, I don't agree with you at all. Mildred Smith. She's your neighbor, my neighbor.
Mildred Smith has no idea about the effectiveness rate. None. You in academia, and
maybe in the research, you understand that, but she doesn't understand that. I'd like to
try to figure out more the third issue of access, to be able to get that and how we might
do that, so that leads me to the next question.
A part of that is obviously, I'm just an engineer. I don't practice medicine, so I'm
curious how we work in -- we seem to be working in a vacuum here in this conversation.
What are they doing in Europe, for example? What's the outbreak? Do we have the
same situation occur in Europe? Do they have a higher vaccination rate? Give me
from a broader perspective than just the United States.
Dr. Messonnier. I think Europe is a broad set of countries, and different
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
countries have different vaccination coverage. But I think many countries struggle with
vaccination coverage against flu. And a lot of countries actually don't have the routine
recommendation that we do or the implementation recommendation.
Mr. McKinley. So you're telling me that if I were to, you know, Google something
here on Europe, I would not find anything because it's limited, or the European Union
does not pull together some data?
Dr. Messonnier. No. I'm sorry. I misunderstood. Of course, there's data. I
don't have it on top of mind, but I'm happy to provide it. But I would like to add --
Mr. McKinley. Well, but I'd like to understand what they're doing in Europe
about this because I know NIH is spending a significant -- maybe not enough but
whatever. What are other countries doing about this? And what advances are they
making towards this universal coverage, if that's a possibility?
And so what's Europe doing on universal coverage, the research in there, and then
also, who are we partnering with? Who's the private sector group because NIH can only
go so far. NIH is not going -- you don't take clinicals to market. Is there someone
that -- are there different firms in the private sector that are showing some participation
in this?
Dr. Messonnier. Maybe I'll just start with one fact and let Dr. Fauci go from
there.
One thing just to point out is that the scientific community for influenza is
incredibly collaborative. And the reason we have such great situational awareness
about strains that are circulating is because countries all over the world, not only in
Europe, but all over the world, gather strains of influenza, provide them to reference
centers, sequence them, and that gives us the information globally about what's
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
circulating.
Mr. McKinley. Okay. Dr. Fauci.
Dr. Fauci. So with regard to the development of vaccines and the technology
and the research, as with almost every aspect of medical research, the United States
clearly dwarfs the other countries. However, the slide that I showed in my presentation
about the strategic plan and research agenda that we put together was based on a
meeting that we held in Rockville in the summer of 2017, and we had international
participation.
So we have good input from people from the Far East, from China, from Europe, et
cetera. But the actual work that's done, although not everything is done in the United
States, an overwhelming proportion of the research and the production on the universal
flu vaccine is done in United States. European countries make their own vaccine.
Mr. McKinley. I hope there's more data. I'm fascinated with that subject and
how it might be able to get to that curve. Let's go back to the initial. If Messonnier did
not have the answer, do any of you know what kind of rates? If we only have, what,
45 -- whatever the rates are.
I've got to admit. I'm one of the guys cheating this -- cheating death on this
because as a senior citizen, I don't get the flu vaccine, and I know I should. I know my
wife does it every year, and she lectures me on this, and I just haven't gotten around to
doing it.
So what are the rates in Europe? Do any of you know?
Dr. Fauci. Yes, we do.
Mr. McKinley. I figured. I didn't ask the right person.
Dr. Fauci. In every single country, for example, I went to a meeting just a couple
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
of months ago on a different subject in France. In France, they do not have the type of
recommendation that we have here which, as Dr. Messonnier said, that everyone
6 months of age or older should be vaccinated.
In several of the top European countries, they vaccinate those who are at highest
risk for complications: the young children, the elderly, those with underlying conditions.
It would be unusual for a European country to have the broad recommendation that we
have of everyone 6 months of age or over to get a vaccine.
Mr. McKinley. Well, I'm just -- the reason I'm raising that question, and the
time's up, I've gone over, is I want to understand a little bit. There in socialized
medicine they have in Europe, I want to see, does that have an impact on it if we were to
implement it?
Ms. DeGette. So the gentleman's time has expired.
Mr. McKinley. I yield back the balance of my time.
Ms. DeGette. The chair now recognizes Mr. Kennedy for 5 minutes.
Mr. Kennedy. Thank you, Madam Chair. I want to thank you for holding this
important hearing and the witnesses for your testimony and your service.
It's clear from what we've heard so far this morning that public health surveillance
tools are critical in monitoring and responding to infectious diseases such as influenza and
other outbreaks across the country.
Unfortunately, a June 2019 report by the Massachusetts Special Commission on
Local and Regional Public Health found that due to inconsistent funding for local public
health agencies, my home State, like many others across the country, has limited capacity
to collect and measure health data.
So beginning with Dr. Messonnier, how does CDC and its partners help States like
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
mine be able to track the spread of influenza from around the country as well as capture
vaccination rates?
Dr. Messonnier. So as you point out, public health runs on data. It's an
incredibly crucial part of our programs. We do provide funding to help health
departments to enable them to work with us on surveillance, and we've been really
innovative. In fact, we've worked with the American Public Health Lab
Association -- sorry, Association of Public Health Labs to build a data system that's
electronic so that the data goes from regional reference labs to the Cloud so that we can
all have access to data sooner.
That being said, the flu program happens to be at the forefront of how we use
data, and in general, the public health data systems are antiquated, and unfortunately,
fragmented, and we really do need to think about new investments if we want the kind of
solid systems that you're talking about.
Mr. Kennedy. So building on that, you said antiquated and fragmented. What
gaps exist specifically in the collection of that data around the spread and severity of the
flu virus?
Dr. Messonnier. Of course, what we'd all want is real-time, actionable data that
can be used at every part of the public health and clinical system. We actually have a lot
of data online now, and you can actually go to our flu site and look at electronic data
that's posted every week that shows what the situation is in flu in every State. What
you'd like to be able to do is use that same picture to click on your State and also
understand vaccination coverage in every corner of your State and the capacity of the
hospital system and whether hospital systems are overwhelmed.
And that's what we're working on is trying to integrate all of that big data to give
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
your State health officials the actionable data that they need.
Mr. Kennedy. Dr. Kadlec, do you have any ideas on the collection of flu and
pandemic data as well?
Dr. Kadlec. Sir, none beyond that has been identified for Dr. Messonnier, but I
think the key thing is to what has been pointed out is that the systems are antiquated and
fragmented. And there is a need to basically enhance those systems so that there is
better real-time data to Dr. Messonnier's point to be actionable.
Mr. Kennedy. And just to be a little more blunt then, if I can, are you suggesting
that Congress -- what actions would you like Congress to take? Is that funding, or is that
additional structures that need to be put in place in order to flush out the system the way
you would want to see it?
Dr. Kadlec. So I think for the purposes of this conversation, I would just note that
there is a multi-year budget that has been put together that looks at pandemic influenza
that's required by Congress. It's a multi-year for the public health emergency medical
countermeasure which identifies that we probably need about $5.7 billion to support
efforts by NIH, FDA and ASPR. But it doesn't include what CDC needs to do for
surveillance and its other programs, important programs for vaccine acceptance.
So I think there's a way to capture this in a way going forward that I think would
holistically represent what is needed to address this challenge broadly. We are
responding to what Congress has identified in one area of this, but I think to Dr.
Messonnier's point, there is a need to basically include these other very important
supporting activities as part of that.
Mr. Kennedy. So it's my understanding, Doctor, that during the 2009 H1N1
outbreak, local health departments did play a key role in the distribution of the vaccine.
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
According to the National Association of County and City Health Officials, since 2008, local
health departments have eliminated a cumulative total of more than 56,000 jobs, a
decrease of about 25 percent of the public health workforce.
Doctor, how do you think ASPR is working with State and local health departments
to prepare for that next flu pandemic?
Dr. Kadlec. Well, I think critically speaking, CDC has an important role to play, a
principal role, and we play a supporting role. There are two grant programs that are
administered by the department, one by CDC dealing specifically with local public health
departments, and the one that ASPR basically administers which is really about hospital
preparedness. And those two things are critically linked in doing that together. And so
we really need to work together to make sure that we capitalize on the public health
infrastructure.
But you have highlighted, I think, a critical reality in the trends of local public
health departments which is not only the graying out of public health departments but
certainly the support they need, subsidies at the State and local level as well as the
Federal level to do this. And I think jointly through CDC and ASPR, we can do better to
do this, but I think quite honestly, that's an area that you've highlighted that is a
vulnerability.
Mr. Kennedy. Thank you, sir. I yield back.
Ms. DeGette. I thank the gentleman.
The chair now recognizes the gentlelady from Indiana for 5 minutes.
Mrs. Brooks. Thank you, Madam Chairwoman, and thank you again for holding
this very important hearing and thank you all for your work.
I'd actually like to go back and allow Dr. Messonnier to answer. Is there anything
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
further you'd like to say that Dr. Kadlec -- and then I have some questions for Dr. Kadlec
because you were nodding quite a bit. But is there anything else you would like to add?
Dr. Messonnier. I was nodding. I think Dr. Kadlec said most of it, but you know,
it is CDC's step program that provides direct funding to States and then from States to
local health departments to specifically work on preparedness capacity.
You can see this capacity used every day at local and State health departments,
both to respond to the everyday emergencies, also to respond to the unexpected
emergencies. And if we fail to invest in those departments, we'll obviously always come
to regret it if we have to rely on them in an emergency.
Mrs. Brooks. Thank you. Thank you.
Dr. Kadlec, I'd like to talk with you. Committee staff recently participated in a
pan flu table top exercise with ASPR, and thank you for that participation. One of the
biggest takeaways was that the U.S. lacks sufficient domestic manufacturing capacity
and/or raw materials for almost all pan influenza medical countermeasures. This is very
concerning.
Further, that global manufacturing capacity would not be sufficient to meet the
demand, so specifically, we have concerns about the United States' supply of needles,
syringes, surgical masks. That was raised during the exercise. We learned that -- and I
think we saw this during Ebola. Surgical masks are not made in the United States, and
so there was a run on masks and other supplies during Ebola.
Can you discuss the challenges we face with respect to those supplies regarding
the lack of domestic manufacturing and the volume we need versus what we currently
have access to in the event of a pandemic?
Dr. Kadlec. Thank you, ma'am, for your question, and yes, it is a significant
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
vulnerability as we look at particularly for pandemic preparedness. Eighty percent of
the materials that we're counting on for, not only just for pandemic support, but
generally in our healthcare system emanate from China and India. So that's both raw
materials, finished products and active pharmaceutical ingredients.
If you had to look specifically at a couple of areas of particular concern around
pandemic influenza preparedness, you would have to look at the antiviral drug supply.
Again, we have about 67 million courses of about 80 million person requirement that we
have in our stockpile, and the active pharmaceutical ingredient comes from Asia at the
present time.
So once we would expend that immediate supply during a pandemic, in order to
manufacture more, there a number of generic manufacturers here domestically in the
United States, but that active pharmaceutical ingredient is -- it would be found in Asia and
would be a critical supply material for any country, much less us.
Mrs. Brooks. What are we doing as the Federal Government to work to address
our domestic manufacturing capacity, whether for the API or --
Dr. Kadlec. Ma'am, on the issues of vaccines alone, I think the key thing is is -- I
can't give you the particulars, but we're going to have an announcement here shortly that
will indicate some investments domestically to expand some of our new
technology -- newer technologies for vaccine manufacturers. And I think the key thing
there is that we're actively pursuing this in accordance with the executive order.
Obviously it's going to be a resource limited kind of activity, but significantly
beyond, that we're really trying to put our arms around this vulnerability in terms of our
supply chain to the other things that you mentioned, surgical masks, latex gloves, other
personal protective equipment, as well as active pharmaceutical ingredients.
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Mrs. Brooks. Is it fair to say that if we're better prepared for seasonal flu
preparedness that that would help us in the event of a pandemic?
Dr. Kadlec. Yes, ma'am.
Mrs. Brooks. And is the H7N9 flu strain still a potential pandemic threat? And
you're all nodding yes, I suppose. And is our prepandemic stockpile adequate right now
relative to that?
Dr. Kadlec. Ma'am, I believe that -- and I would turn to Dr. Messonnier and Dr.
Fauci for their answer, but my understanding is that it's not a good match with the
current circulating strains, so its utility would be limited.
Mrs. Brooks. Dr. Fauci?
Dr. Fauci. I agree. It's another example of the virus changing. We made a
vaccine back in 2013, and we get to 2018, 2019, and it's a bit different, so it would not be
a good match.
Mrs. Brooks. And given ASPR's support for developing new antiviral products,
how would adding new antivirals to the stockpile increase our preparedness? And
how -- what is the -- what's the time that it takes and the money that it takes to add new
antivirals to our stockpile?
Dr. Kadlec. Ma'am, very briefly, I think the risk that you're trying to mitigate is
the risk that over time, circulating flu strains will be resistant to what we have in our
stockpile which is Tamiflu. And currently, there is evidence of that in the world today.
The real reality is how much does it cost. Newer classes of antibiotics tend to be
more expensive, and so it would be a much more significant investment in terms of
replacing our existing stockpile.
And we're evaluating what's the mix that we need to have which gives us the
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
advantage over what we have in our stockpile, what do we need to buy or purchase that
would basically minimize or mitigate our risk to future strains.
Mrs. Brooks. Thank you.
I yield back.
Ms. DeGette. Dr. Kadlec, I just wanted to follow up on something Mrs. Brooks
asked you. You said a big announcement about domestic production is going to be
made. When will that announcement be made, do you expect?
Dr. Kadlec. Ma'am, I'm hopeful by next week.
Ms. DeGette. By next week. Okay. That will be -- that will be ready good.
Thank you.
The chair now recognizes Ms. Kuster for 5 minutes.
Ms. Kuster. Thank you very much, and thank you, Madam Chair, for holding this
timely hearing this week during National Influenza Vaccination Week.
In my home State of New Hampshire, 40 people lost their lives in the last flu
season, and of particular concern to me is the impact on seniors. You can imagine in the
winter driving through rural New Hampshire is hard enough, but if you're an ill senior,
that is really difficult. So I want to thank you all for being with us.
I want to focus in on the seasonal flu vaccine last year was more effective for the
first primary strain, but its effectiveness rate dropped significantly later in the season
when the dominant strain in the United States changed. And unfortunately, the longer
season and the shift in flu strain, as I mentioned, led to 40 deaths in my State.
Dr. Fauci, what do you mean when we talk about vaccine effectiveness, and how is
it measured?
Dr. Fauci. Vaccine effectiveness is really a percent of protection based on a
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
comparison to people who are not vaccinated. So if you have 100 percent effectiveness
which you almost never have, that would be essentially everybody gets protected who
gets vaccinated. The percentage goes down as you have people who are vaccinated but
who actually do get infected.
Ms. Kuster. Have flu symptoms?
Dr. Fauci. Right.
Ms. Kuster. All right. And how does the effectiveness of last year's vaccine
compare to those in the past? And will we -- when we will know how effective this
year's vaccine is?
Dr. Fauci. Well, if you look at last year's effectiveness, you have to be careful to
make sure that you can pick -- that you look at H3N2 compared to H1N1 because when
we vaccinate, we vaccinate against H3N2, H1N1, and B, actually two Bs. So when you
look at the H3N2, I believe it was 29 percent, if I'm not mistaken. It was 29 percent
effective against H3N2.
And if you look at the chart -- I'm speaking, but Nancy has it. If you look at the
chart that the CDC puts out, they give each year what the effectiveness is. It really is a
wide range. There's a very good year where you can get 60 percent.
The average is somewhere between 40, 50 percent or so. On a very bad year,
you could go down to around 10 percent. When I say that, I say it with some degree of
nervousness. It's still always better to get vaccinated regardless of what that percent is.
Ms. Kuster. Well, I want to get to that with Dr. Messonnier. Why is it so
important for people for whom the vaccine may currently be less effective such as seniors
to get the flu vaccine each season?
Dr. Messonnier. Thank you. Maybe just to go back to a question that you
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
asked, this one strain, the H3N2 strain which was the strain that caused that second peak
last year, happens to be a particularly difficult strain in terms of vaccine effectiveness.
But if you look historically, the range of the effectiveness of that strain is always harder
because of the reasons that Dr. Kadlec and Dr. Fauci mentioned earlier. We'll have
preliminary estimates of the vaccine effectiveness, this season's vaccine, in February, and
then our final estimates should be available in the summer.
The larger issue is when Dr. Fauci referred to vaccine effectiveness, but we have to
remember that even if the vaccine is not perfectly effective against any influenza, it still
can be effective against more severe influenza and against death. And so even in a year
where the overall vaccine effectiveness is not as great, vaccine effectiveness against more
severe illness can actually be high. It's always better to get vaccinated than not.
Ms. Kuster. So we should be encouraging our constituents to get the vaccine.
The symptoms will be milder, and we should --
Dr. Messonnier. Everybody should get the vaccine because today I can't totally
predict what the season is going to be like, and my kids are vaccinated. My parents are
vaccinated. Of course, I'm vaccinated.
Ms. Kuster. And I will be as well. Thank you.
Dr. Marks, you stated in your testimony that the FDA conducts, quote, applied
scientific research to address current challenges in season and pandemic influenza
vaccine production, including improving their effectiveness. What specific research
efforts is the FDA currently engaged in to improve vaccine effectiveness rates, particularly
for those populations less protected by recent flu vaccines.
Dr. Marks. Thank you for that question. So we are engaged in research that's
looking mainly to try to improve the ability to produce influenza vaccines on a rapid basis.
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
We have some work that's going on that essentially builds off of NIH's work on trying to
make a more effective vaccine.
But one of our major -- the major thrusts of work from FDA's perspective is trying
to be able to be agile in our manufacturing, to look at things like advanced manufacturing
technologies such as continuous manufacturing which could allow us to actually have
seasonal influenza or pandemic influenza vaccines produced at a much greater quantity,
in a much smaller footprint, on U.S. soil in the event of a pandemic which I think is one of
the things that, as Dr. Kadlec mentioned, is important for national security.
Ms. Kuster. Great. Thank you.
My time is up. I yield back.
Ms. DeGette. The chair now yields 5 minutes to the gentleman from Texas,
Mr. Burgess.
Mr. Burgess. Thank you, and thanks to the panel for being here. I apologize.
I've been upstairs at a cosmetics hearing. That's why I look so youthful.
Since I haven't been here, I haven't heard all of the questions that have been
asked, so if I do something that's duplicative, I apologize about that. But Dr. Messonnier
and maybe Dr. Kadlec, the issue of the vaccination at facilities for Customs and Border
Protection has apparently come up. We had a hearing, I think we held a subcommittee
in September, and also addressed this. I've traveled to many of the Customs and Border
Protection facilities on the border in Texas, specifically Clint and the Ursula facility down
at McAllen. I actually went to the Ursula facility at McAllen with a DHS physician who
was on that trip.
So when this issue came up, I called that person and said hey, does DHS not do
this, and he said no, DHS has given -- and I forget the figure, and Dr. Kadlec, you may be
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
able to supply it, but tens of thousands of doses of flu vaccine are administered by the
Department of Homeland Security.
I guess the issue is if they are in a facility that's only going to retain them for 12 to
72 hours, and then they're going to a Health and Human Services facility, and we're
prominently talking about children here going to a Health and Human Services facility or
an ORR facility where they will be for perhaps several weeks, I think it makes sense to do
the vaccination at the ORR facility.
Now, I know there was an issue because Congress was late in supplying some
supplemental funding for Department of Homeland Security. They got backed up with
the number of people that were coming across the border in May and the early part of
June, so people were held at CBP facilities for longer than what was ideal.
But if the difficulty is we weren't providing DHS with the funding to do their
primary job in the first place, I don't know where they were supposed to get the money
to buy additional flu vaccine, but I suppose that's a separate story.
But can you talk at all about how you've coordinated with Customs and Border
Protection and the Department of Homeland Security more specifically about your
recommendations and what they see as their role?
Dr. Messonnier. Sure. And I apologize for repeating myself, but we were
contacted by DHS last December, and we provided technical consultation in December
and January that led to an oral report out and then a written report which was entered
into the record. And what we recommended was what we would generally say, that the
priority be given to infection control, identification, and isolation of the migrants, early
provision of antivirals, and priority to vaccination of the DHS staff.
Our report goes on to say as consistent with our general recommendations for
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
everybody in the United States, we would recommend a flu vaccine for everybody
6 months of age and older at the earliest operationally feasible time.
Mr. Burgess. So children that are held in Office of Refugee Resettlement
facilities are going to receive the full complement of childhood vaccines as just part of the
course. I think that's one of the things that's evolved since 2014.
Dr. Messonnier. That's right.
Mr. Burgess. Because we don't know the vaccine history, we just provide the
vaccines. It seems like it would make sense to provide the flu vaccine at that interval
because that's done relatively early in their stay in an HHS facility.
Dr. Messonnier. That's correct. Children within ORR are given both the
childhood vaccines and their flu vaccines, and my understanding is coverage is high.
Another complication of this, as you point out, is the medical records which don't come
with those children.
Mr. Burgess. Right.
Dr. Messonnier. They err on the side of protecting them with the vaccine.
Mr. Burgess. And, of course, what they do come with is the flu sometimes
because they are held in less than ideal facilities referred to as stash houses on the other
side of the border and then brought over when it's convenient with the coyotes or the
cartels. They don't provide vaccination services on their side, and so they end up in our
facilities oftentimes very, very ill.
Well, I'd like to see us do -- if we're not doing a good job with coordinating
between the two agencies, I'd like to see that as part of the exercise that comes out of
this. Once again, my thanks to everyone who is on the panel.
Some of my favorite people in the world are on this panel, so I appreciate you
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
being here and participating in our hearing today.
Thank you, and I yield back.
Ms. DeGette. I thank the gentleman.
The chair now recognizes the gentlelady from Florida for 5 minutes.
Ms. Castor. Well, thank you, Chairwoman DeGette, for calling this hearing.
Dr. Messonnier and Fauci, we had the benefit of your testimony before the
subcommittee earlier this year, the measles hearing where you both stressed the
importance of vaccinations for infectious diseases. And I wanted to talk a little bit about
that in regards to the flu, but looking at the CDC's statistics over the last, 50, 60 years.
I think for measles, what was remarkable was that in the 1950s and 1960s where
you had hundreds of thousands of people dying from that disease, the measles vaccine
practically eradicated measles, and the big concern was now that people were skipping
that vaccine, and it could make a comeback.
With flu, what really stands out are the high numbers still of people who come
down with the illness, who are hospitalized and even die because -- and that's largely
because the flu strains change over time. Is that right?
Dr. Fauci. Yes. Well, you compared measles with flu which is something we
discussed at the last hearing. So the measles that I, unfortunately, got infected with
when I was a child is not particularly different from the measles that we have circulating
right now. It just doesn't change. And that's the reason why a highly effective vaccine
like measles which is 97 percent, at least, effective can essentially eliminate measles from
certain parts of the world.
But influenza, we're constantly chasing it. It continually evolves. It continually
mutates. And that's really the reason why we need to do better with seasonal flu
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
vaccines, but we also need to get a universal vaccine that would cover those kinds of
changes that occur.
Ms. Castor. And it's so heartening to hear about the progress being done there,
but the current vaccines are safe and effective. I think you've all testified to that. So
I'd like to focus on the availability. Dr. Messonnier, is the flu vaccine widely available
currently?
Dr. Messonnier. Yes. Flu vaccine is widely available currently and we watch
carefully across the United States to make sure that consumers aren't experiencing any
shortages. You know, the last thing we want is for someone to show up in a doctor's
office asking for the flu vaccine and be turned away because --
Ms. Castor. Right. And you said one of the reasons that people often skip it
is the-- skip the flu vaccine is because they're skeptical it's effective, and some people skip
it because maybe they do run into a barrier. But I think working together over time,
we've made a lot of progress on that.
Now under the Affordable Care Act, the vaccine is covered, so it should be free if
you have a policy under healthcare.gov. Most standard insurance policies cover this
because everyone realizes, boy, it's a whole lot less expensive to get the flu vaccine than
to miss a week or 10 days of work or something even more serious.
I looked up for the State of Florida, the Florida Department of Health,
floridahealth.gov. You can find, you can locate where your -- where to get your vaccine,
but it's fairly easy now. The Veterans Administration, you can get a free flu shot there.
Community health centers all over your neighborhoods, you can get your flu vaccine.
Oftentimes your employers, colleges and universities do that because that's the
last thing they want is students and professors being infected. Most grocery stores and
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
pharmacies now, you can walk right in because I think sometimes it's a convenience.
People are busy with their lives.
Are there any other barriers that we need to be working on to ensure that
people -- that there's not a cost barrier or just the access?
Dr. Messonnier. Thank you for those comments, and I think, you know, in
addition to the issue with the vaccine effectiveness that Dr. Fauci talked about, certainly a
big difference between where we are with measles and influenza is vaccination coverage.
And as you point out, it is a good buy for people as individuals and businesses to
keep their employees safe. And health systems, we can actually show that, for example,
in people over 65, it's much more effective from a cost perspective to prevent the flu
than it is to take care of people once they get sick.
And I think the final thing that you were mentioning is really important which is
we need to make it easy for people to make the healthy choice for themselves and their
families by making it easy for them to get the flu vaccine.
Half of adults are actually getting vaccinated outside their medical -- their doctor's
office. They're getting vaccinated at pharmacies and drug stores and supermarkets, and
they're getting vaccinated in the workplace. Children, some States have actually had a
lot of success in school-based vaccination programs where kids are vaccinated while
they're in school, making it much more convenient for parents.
And one of the things that we're doing is exploring all of those strategies to see
what we can do again to make it easy for people to make healthy decisions.
Ms. Castor. Well, I've had my flu shot, and everyone in my office, we have a let's
get our flu shot day, and everyone -- we apply a little peer pressure for those that might
need it because it's so important. We want everyone to be healthy and well. And if
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
you haven't gotten your flu shot yet, you better go out today and go ahead and do that.
Thank you.
Ms. DeGette. I thank the gentlelady.
The chair now recognizes the gentleman from Virginia for 5 minutes.
Mr. Griffith. Thank you very much, Madam Chair.
Congresswoman Castor set up one of my questions very well, Dr. Messonnier.
She said that, you know, you can go to the VA and get your shot. Most of the studies
that have been done on the -- let me make sure I get the wording correct -- the high dose
vaccine have shown that it's much more effective for people over the age of 65 which was
a part of your answer back to her. But because the CDC has not made that a
preferred -- let me make sure I get -- a preferred recommendation, the VA hospitals can't
give that to people over 65, so they have to go somewhere else. A lot of doctors are
giving it, but the VA can't give it.
So that being said, with the studies out there, what do we need to do to get the
CDC to make this a preferred recommendation for the high dose flu vaccine because it
looks like we're -- you know, she mentioned it, not knowing I was going in this direction,
that a lot of people go to the VA Hospital, and a lot of our veterans do.
But if you're over the age of 65, you probably ought to be getting this not yet CDC
preferred treatment, but the high dose vaccine, but you're not able to get it there.
Dr. Messonnier. Actually, thank you for the opportunity to comment on this.
There are actually nine different flu vaccines available this season, and eight of those are
licensed for people over 65. So the complication is the comparison of every single one
of those products to know which ones are better and which ones are not.
CDC, as I expect you would not be surprised, understandably cautious about
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
making preferential recommendations because we need to be sure that a vaccine that
we're going to prefer is not just effective this season but is effective, is preferential,
better, every season. And since every flu season is so different, we tend to be cautious.
That being said, we're taking this issue very seriously. Since last year, we've
launched new, more robust studies to examine the vaccines that are available in this age
group, and we have an interagency working group with our Federal partners so that we
can make sure that we're covering all the watershed of all the studies that need to be
done.
We've also put this back to our advisory committee to ask them to look again at
the available data and consider this issue. The issue will be considered as all of these
issues are in our public meeting where folks can see the debate and see how they
come -- you know, what conclusions they come to.
So we take the issue very seriously, but again, understandably cautious about
making a recommendation like that.
Mr. Griffith. But you said eight of the nine are actually considered preferred.
Dr. Messonnier. No, licensed. Of the nine available vaccines, eight of them are
licensed for people over 65.
Mr. Griffith. Okay. But this is dealing with the high dose vaccine, and according
to the data I have here, there have been 14 studies over nine consecutive seasons, 14
million study participants, and only one of those studies did not say that it was preferred
or that it was better for people over the age of 65 to get the high dose vaccine.
Dr. Messonnier. So that is a comparison of one company's high dose vaccine
against the same company's regular dose vaccine.
Mr. Griffith. Uh-huh.
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Dr. Messonnier. The problem is that there are more than one high dose vaccine
and also adjuvanted vaccines in that age group. The other issue, back to the issue Dr.
Fauci was talking about, is that we need to make sure that it's preferential -- that it's
more effective against every one of the potential strains of flu vaccine which means we
need more robust data, not just effectiveness against H1N1 but against H3N2 and both
types of B, be confident that a preferential recommendation will be right every single
season.
Mr. Griffith. Well, in the absence of a preferential recommendation, can you
work with the VA? Will you work with the VA to ensure that our veterans over age 65
can receive the high dose vaccine if their doctor thinks that's appropriate?
Dr. Messonnier. We're obviously always happy to work with the VA, and they
are a part of this interagency working group where we're really robustly trying to get the
data together to look at this issue really seriously.
Mr. Griffith. Because outside of the VA, a lot of doctors are recommending that
for their patients.
All right. Switching gears because I've just got a few seconds left, and I'm just
going to make a comment. If we have time, Dr. Kadlec and Dr. Fauci, you all can
respond, but we keep waiting. I've been here now 9 years which is not nearly as long as
some of the members of this committee, and every year we hear that we're almost there.
We're getting there. We hear -- we see great slides, and you all do great work.
And Dr. Burgess said you are all some of his favorite people. I would agree with
that. You all are doing great work, but you know, is this year going to be any different?
Are we going to come back next year, and again, we still won't have something that's a
non egg-based vaccine?
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
Dr. Fauci. We certainly are better off this year than we were last year in our
quest for a universal flu vaccine. Last year we didn't even have a candidate.
This year, we're now 8 months in phase one, and by early 2020, we'll know clearly
is it safe, and does it induce the kind of response that you would predict would be
protective. So clearly, there's a difference between the last time we spoke at the
hearing.
Mr. Griffith. Yeah. And there's always advancement. I'm just looking for that
day when there's -- coming from a family with a lot egg-based vaccine problems because
of the egg-based situation, I'm really looking forward to the day when we can say that we
have more than 50 percent of the vaccine out there is non-egg based.
I yield back, Madam Chair.
Ms. DeGette. I thank the gentleman. The gentleman missed the slide
presentation, and so we will be --
Mr. Griffith. No. I saw the slide presentation, or I would have had a much
more biting question. But the presentation was great. I saw it. It was good.
Ms. DeGette. We'll get you a copy.
The chair now recognizes the gentlelady from New York for 5 minutes.
Ms. Clarke. Thank you, Madam Chair, and I thank our Ranking Member Guthrie
for convening this very important hearing on the influenza virus and what can be done
across the Federal Government to improve and protect public health as we near peak flu
season here in the United States.
I want to thank our expert witnesses for being here today to testify on behalf of
the CDC, NIH, HHS, and the FDA.
And while the national targets for vaccination rates for the past decade have
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
ranged from 70 to 90 percent, depending on the population, it appears as though we are
falling woefully short of these goals. Last season, only 43 percent of adults and
63 percent of children received their annual flu vaccine.
I'd like to better understand why these vaccination rates continue to be so low
and what we can do to improve these numbers overall, also, specifically, what
underserved populations. So Dr. Messonnier, what trend has CDC identified in recent
years with regard to flu vaccination rates, and where are we making progress? Where
are we falling short?
Dr. Messonnier. So I share your concern and your frustration that vaccination
rates for influenza are lower than we want them to be. There has been a 5 to 8 percent
increase in coverage from one year to the next, so the recent trends are optimistic, but
history has shown us that, you know, that may not hold true.
And I think as you've said, we have studied this issue. When we survey people to
ask why they don't get the flu vaccine, what they say is that they don't think it works,
they're concerned that it's not safe, and oh, well, flu isn't that serious.
We definitely also know that we see lower vaccination coverage rates in rural
areas, in people of lower socioeconomic status, and the data really does indicate that
especially when people aren't convinced of the value of a flu vaccine, how easy it is to get
the vaccine matters.
Ms. Clarke. Are there particular populations who face barriers to accessing the
flu vaccine, resulting in coverage disparities?
Dr. Messonnier. I think that our data suggest people of lower socioeconomic
status, people without health insurance, people in rural areas, this is data in children,
have lower vaccination rates. I'm especially concerned with the issue for children
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
because the vaccines for children's program provides a safety net for children who can't
afford vaccines. Those children should be able to get vaccines easily, and yet,
vaccination coverage for children is still unacceptably low.
Ms. Clarke. Dr. Marks, you've already attested to the safety of the flu vaccine.
Unlike other vaccines, however, the flu vaccine is recommended every season over the
course of a person's life. What can you tell us about the studies that have looked into
the long-term effects of the flu vaccine to calm concerns people may have? And I know
you've said some of it already here today, but I think it's worth reiterating.
Dr. Marks. Thanks very much for that question.
So both for childhood vaccines and for adult vaccines, there have been numerous
studies that have looked at the vaccination schedules and at repeated vaccination, and
FDA continues to use its large database surveillance systems to look at the safety of
vaccines. All indications are that the current vaccine regimens are safe and effective for
their -- in their intended schedules and there's really no reason not to get vaccinated
routinely and that the benefits greatly outweigh any risks.
Any medical intervention has small risks, but vaccines are among the most
amazing health interventions of the 20th century and of the 21st century, that is, in terms
of being public health interventions that have reduced illness and prevented deaths.
Ms. Clarke. And, Dr. Fauci, according to your testimony, over the last 15 years,
the effectiveness of seasonal influenza vaccines have ranged from 10 to 60 percent.
Why does NIH, along with your fellow public health agencies, still recommend the flu
vaccine each season?
Dr. Fauci. Thank you for that question, and it's really an important question.
When you talk about effectiveness, you've got to understand that even if a vaccine is not
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
effective in preventing infection, it can clearly mitigate the seriousness of the illness,
prevent hospitalization, and certainly prevent death.
And that's the reason why you've heard all of us say regardless of what the
percent efficacy is on a chart, it is always better to get vaccinated than not to get
vaccinated because some degree of protection, either against infection or the
complications of infection are very important and advantageous. So many lives are
saved, many, many lives, even with a vaccine that is not optimally protective.
Ms. Clarke. Very well. It is clear that more needs to be done to increase the
number of people who get vaccinated, particularly for those more vulnerable to the flu
and marginalized from care.
And improving the vaccination rate will not only serve public health in the broad
sense, it would also save lives. And I think there's an appointment at the attending
physician with my name on it.
I yield back, Madam Chair.
Ms. DeGette. I thank the gentlelady.
I want to thank the witnesses for coming today. In case there's any mistake, the
unified, bipartisan message from this hearing is get your flu shot. This week's a good
time to do it because it's the flu shot week, and we don't know how bad this season's
going to be, so everybody needs to get their flu shot.
It's hard to get such bipartisanship that we were up here saying the members felt
like we could all exchange opening statements and give each other's opening statements,
and they would still have the same impact. So it's really important that people get their
flu shots.
I want to remind members that pursuant to the committee rules, they have 10
This is a preliminary, unedited transcript. The statements within may be inaccurate, incomplete, or misattributed to the speaker. A link to the final, official transcript will be posted on the Committee’s website as soon as it is available.
business days to submit additional questions for the record to be answered by witnesses
who have appeared before the subcommittee. I ask the witnesses to respond promptly
to any such questions should you receive any, and with that, the subcommittee is
adjourned.
[Whereupon, at 12:13 p.m., the subcommittee was adjourned.]